Combination of Cisplatin, Docetaxel and Bevacizumab in Patients With Non-small Cell Lung Carcinoma (NSCLC)

Inclusion Criteria: * Histologically or cytologically documented inoperable, locally advanced, metastatic or recurrent NSCLC other than squamous cell * At least 1 measurable lesion according to RECIST criteria * ECOG performance score 0 or 1 * Age between 18 and 70 years Exclusion Criteria: * Mixed, non-small cell and small cell tumours or mixed adenosquamous carcinomas with a predominant squamous component. * History of haemoptysis * Evidence of tumour invading major blood vessels on imaging. * Previous neoadjuvant/adjuvant chemotherapy. * Previous radiotherapy. * Serious uncontrolled coagulation disorder or thrombo-embolic complications within 6 months prior to study start or history of serious bleeding complications. * Major surgical procedures within 4 weeks prior to study entry. * Minor surgery, including insertion of an indwelling catheter, within 24 hours prior to the first bevacizumab infusion. * Non-healing wound, active peptic ulcer or bone fracture. * History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months of enrolment.